News

According to the clinical development agreement, Protalix will continue to manage and fund Elelyso (taliglucerase alfa) ongoing trials while the new studies of the enzyme replacement therapy will

The companies are also considering signing a licensing contract to develop new DuoBody product. Genmab’s DuoBody platform swiftly generates bispecific antibodies through a process performed at standard bench,

The collaboration will make use of Amorfix’s ProMIS discovery technology and the terms of the deal are kept confidential. Amorfix president and CEO Dr. Robert Gundel said, "This

Health Canada has also started enquiring the company’s customers regarding the ways and means used by it in testing a product. According to Health Canada’s enquiry, the company

The Patent No. 8,324,266 covers methods for treating pulmonary disease using Pearl’s co-suspension technology in metered-dose inhalers (MDIs). The technology is used in PT003, a fixed dose combination

In exchange, uniQure granted Benitec a non-exclusive access to its AAV5 delivery technology for the development of a ddRNAi therapy for Hepatitis B. Benitec’s ddRNAi technology has the

The CNS Black supplement can be used by elite athlete or people who deal with a lot of stress and daily pressure. Containing a naturally non-essential amino acid,

Cenduit chief executive officer Jogin Desai said clinical trials are complex than ever and a reliable clinical trial supply strategy is important to study success. "The simulation and

New technique is designed for unlimited stem cell and derivative production besides significant reduction in the production time and reduction in the risk of teratomas. Salk scientists modified